Zacks Research Issues Pessimistic Outlook for PLX Earnings

Key Points

• Zacks Research lowered its Q3 2026 EPS estimate for Protalix BioTherapeutics to a loss of $0.05 per share from a prior loss estimate of $0.03. The firm also projected losses for Q4 2026 and FY2027.
• PLX shares rose 0.4% to open at $2.35, with the stock trading near its 50-day and 200-day moving averages. Protalix has a market capitalization of approximately $189 million.
• Institutional ownership remains limited at 16.53%, although several investors—including Bank of America and BNP Paribas Financial Markets—recently increased their positions.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Investment analysts at Zacks Research dropped their Q3 2026 earnings per share estimates for Protalix BioTherapeutics in a report released on Thursday, August 13th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics' Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at $0.19 EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.02 EPS.

Protalix BioTherapeutics Stock Up 0.4%

Shares of PLX stock opened at $2.35 on Thursday. The stock has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $2.36. Protalix BioTherapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $3.19. The stock has a market capitalization of $189.34 million, a P/E ratio of -18.08 and a beta of 0.02.

Institutional Investors Weigh In On Protalix BioTherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd purchased a new stake in shares of Protalix BioTherapeutics during the fourth quarter valued at $26,000. Equitable Holdings Inc. purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth about $31,000. Ieq Capital LLC purchased a new position in Protalix BioTherapeutics in the 2nd quarter worth about $32,000. Bank of America Corp DE raised its holdings in Protalix BioTherapeutics by 364,766.7% during the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company's stock worth $32,000 after buying an additional 21,886 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Protalix BioTherapeutics by 126.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company's stock worth $34,000 after buying an additional 8,498 shares during the period. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source